Biopharmaceutical company PolyPid Ltd said on Monday that it will proceed with its phase 3 clinical trial of its lead asset D-PLEX[100] for the prevention of post-cardiac surgery sternal Infections following the US Food and Drug Administration (FDA) review of the IND.
This phase 3 clinical trial is a prospective, multinational, multicentre, randomised, single blind, study to assess the efficacy and safety of D-PLEX[100] in prevention of post-cardiac surgery sternal infections.
Following the US FDA approval, the multinational Phase 3 study is expected to start in the first half of 2019.
The company's lead product candidate, D-PLEX[100], is a novel product designed to provide local anti-bacterial activity directly at the surgical site to prevent surgical site infections. Following D-PLEX[100] administration into the surgical site, the drug reservoir constantly releases the entrapped broad-spectrum antibiotic in a controlled manner over a predetermined period of four weeks, thus allowing prolonged infection management with increased potential to eradicate antibiotic resistant bacteria.
According to the company, its transformational PLEX (Polymer-Lipid Encapsulation Matrix) -based products have demonstrated an excellent efficacy and safety profile during extended clinical trials, with more than 100 patients treated in clinical trials to date.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal